THE SOCIETAL IMPACT OF LENALIDOMIDE IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA IN GERMANY

被引：0
|
作者：
Hofmann, S. [1 ]
Seddik, A. [1 ]
机构：
[1] WifOR, Darmstadt, HE, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN216
引用
收藏
页码：S478 / S478
页数：1
相关论文
共 50 条
  • [11] Lenalidomide for the treatment of relapsed multiple myeloma
    Gajraj, Elangovan
    Chung, Helen
    Boysen, Meindert
    Barnett, David B.
    Longson, Carole
    LANCET ONCOLOGY, 2009, 10 (07): : 647 - 648
  • [12] THE IMPACT OF TREATMENT PERSISTENCE WITH LENALIDOMIDE (LEN) FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) ON DISEASE CONTROL
    Henk, H.
    Kaura, S.
    Khan, Z.
    Teitelbaum, A.
    VALUE IN HEALTH, 2012, 15 (07) : A410 - A411
  • [13] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Takashi Yoshida
    Masaki Ri
    Haruna Fujinami
    Yoshiko Oshima
    Takuto Tachita
    Yoshiaki Marumo
    Hirokazu Sasaki
    Shiori Kinoshita
    Haruhito Totani
    Tomoko Narita
    Ayako Masaki
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2019, 110 : 228 - 236
  • [14] Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens
    Reece, Donna E.
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Jimenez-Zepeda, Victor
    McCurdy, Arleigh
    Song, Kevin
    Sebag, Michael
    Leblanc, Richard
    Louzada, Martha L.
    White, Darrell J.
    Stakiw, Julie
    Reiman, Tony
    Kotb, Rami
    Aslam, Muhammad
    Gul, Engin
    Venner, Christopher P.
    BLOOD, 2019, 134
  • [15] CHEMOMOBILIZATION WITH CYCLOPHOSPHAMIDE AND FILGRASTIM IN MULTIPLE MYELOMA PATIENTS FOLLOWING LENALIDOMIDE TREATMENT
    Gerfen, A. D.
    Campen, C. J.
    Yeager, A. M.
    Green, M. R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S349 - S350
  • [16] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Yoshida, Takashi
    Ri, Masaki
    Fujinami, Haruna
    Oshima, Yoshiko
    Tachita, Takuto
    Marumo, Yoshiaki
    Sasaki, Hirokazu
    Kinoshita, Shiori
    Totani, Haruhito
    Narita, Tomoko
    Masaki, Ayako
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (02) : 228 - 236
  • [17] Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
    Moreau, Philippe
    Zamagni, Elena
    Mateos, Maria-Victoria
    BLOOD CANCER JOURNAL, 2019, 9 (4)
  • [18] Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
    Philippe Moreau
    Elena Zamagni
    Maria-Victoria Mateos
    Blood Cancer Journal, 9
  • [19] An update on the use of lenalidomide for the treatment of multiple myeloma
    Zagouri, Flora
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (12) : 1865 - 1877
  • [20] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
12345